Thepursuit of NF-kB inhibitors for cancer therapy will be tempered, however, bythe paradoxical observations that inhibition of NF-kB can also contribute totumor development in xenografts and mouse models of skin cancer, and thatexpression of β-catenin and HSCO has been shown to promoteoncogenesis - at least in part - by inhibiting NF-kB[5,6,19-21]. This evidence concerns the gene NFKB1 and cancer.